EP1139751A4 - EFFICIENT AND STABLE -I (IN VIVO) GENE TRANSFER TO CARDIOMYCETS USING RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS - Google Patents

EFFICIENT AND STABLE -I (IN VIVO) GENE TRANSFER TO CARDIOMYCETS USING RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS

Info

Publication number
EP1139751A4
EP1139751A4 EP99967703A EP99967703A EP1139751A4 EP 1139751 A4 EP1139751 A4 EP 1139751A4 EP 99967703 A EP99967703 A EP 99967703A EP 99967703 A EP99967703 A EP 99967703A EP 1139751 A4 EP1139751 A4 EP 1139751A4
Authority
EP
European Patent Office
Prior art keywords
cardiomyocytes
vivo
efficient
stable
gene transfer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP99967703A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1139751A1 (en
Inventor
Jeffrey M Leiden
Eric Svensson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Development Corp
Original Assignee
Arch Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Development Corp filed Critical Arch Development Corp
Publication of EP1139751A1 publication Critical patent/EP1139751A1/en
Publication of EP1139751A4 publication Critical patent/EP1139751A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP99967703A 1998-12-28 1999-12-28 EFFICIENT AND STABLE -I (IN VIVO) GENE TRANSFER TO CARDIOMYCETS USING RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS Ceased EP1139751A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11392398P 1998-12-28 1998-12-28
US113923P 1998-12-28
PCT/US1999/031093 WO2000038518A1 (en) 1998-12-28 1999-12-28 Efficient and stable (in vivo) gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors

Publications (2)

Publication Number Publication Date
EP1139751A1 EP1139751A1 (en) 2001-10-10
EP1139751A4 true EP1139751A4 (en) 2003-03-19

Family

ID=22352321

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99967703A Ceased EP1139751A4 (en) 1998-12-28 1999-12-28 EFFICIENT AND STABLE -I (IN VIVO) GENE TRANSFER TO CARDIOMYCETS USING RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS

Country Status (5)

Country Link
EP (1) EP1139751A4 (cg-RX-API-DMAC7.html)
JP (1) JP2002533359A (cg-RX-API-DMAC7.html)
AU (1) AU763049B2 (cg-RX-API-DMAC7.html)
CA (1) CA2356551A1 (cg-RX-API-DMAC7.html)
WO (1) WO2000038518A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745416B2 (en) * 1995-04-11 2010-06-29 The Regents Of The University Of California Method for in vivo regulation of cardiac muscle contractility
HK1048593A1 (zh) * 1999-11-05 2003-04-11 The Regents Of The University Of California 用於通过体内基因输送治疗心血管疾病的技术和组合物
EP1870473A1 (en) * 2000-08-17 2007-12-26 Keiya Ozawa Adeno-associated virus-mediated delivery of angiogenic factors
ES2288993T3 (es) * 2000-08-17 2008-02-01 Keiya Ozawa Distribucion de factores angiogenicos mediada por virus adenoasociados.
EP1324780A4 (en) * 2000-09-06 2005-06-22 Univ Johns Hopkins METHODS OF TREATING CARDIAC ARRHYTHMIA
US20030022870A1 (en) * 2001-06-01 2003-01-30 Victor Dzau Methods of treating cardiac disorders
AU2003299204A1 (en) 2002-10-02 2004-04-23 The Johns Hopkins University Focal calcium channel modulation
US20070134204A1 (en) * 2005-12-09 2007-06-14 Henrich Cheng Method for treating nerve injury and vector construct for the same
PL2044199T3 (pl) * 2006-07-25 2013-04-30 Celladon Corp Przedłużony, podawany z prądem krwi, nasierdziowy, wieńcowy wlew wektorów wirusowych na bazie wirusów towarzyszących adenowirusom, zawierający SERCA2a do terapii genowej
EP2244740A1 (en) 2008-02-19 2010-11-03 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium
CA2837322C (en) * 2011-05-26 2023-03-21 University Of Washington Cell and gene based methods to improve cardiac function
US12064470B2 (en) 2017-11-16 2024-08-20 Universite D'aix-Marseille FGF10 for the treatment of heart diseases
CA3099958A1 (en) 2018-04-16 2019-10-24 The Trustees Of The University Of Pennsylvania Compositions and methods for treating duchenne muscular dystrophy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012050A1 (en) * 1995-09-27 1997-04-03 The Rockefeller University Method for transferring genes to the heart using aav vectors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792483A (en) * 1993-04-05 1998-08-11 Vickers, Inc. Injection molding machine with an electric drive

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012050A1 (en) * 1995-09-27 1997-04-03 The Rockefeller University Method for transferring genes to the heart using aav vectors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KESSLER P D ET AL: "SODIUM BUTYRATE GREATLY ENHANCES THE EFFICIENCY OF VIRAL TRANSDUCTION IN ADULT VENTRICULAR CARDIOMYOCYTES BY ADENO-ASSOCIATED VIRAL VECTORS", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, vol. 92, no. 8, 15 October 1995 (1995-10-15), pages 1408, XP000673503, ISSN: 0009-7322 *
MAEDA ET AL: "Efficient Gene Transfer into Cardiac Myocytes Using Adeno-Associated Virus (AAV) Vectors", J MOL CELL CARDIOL, vol. 30, July 1998 (1998-07-01), pages 1341 - 1348 *
See also references of WO0038518A1 *

Also Published As

Publication number Publication date
CA2356551A1 (en) 2000-07-06
WO2000038518A1 (en) 2000-07-06
AU763049B2 (en) 2003-07-10
JP2002533359A (ja) 2002-10-08
AU2394200A (en) 2000-07-31
WO2000038518A9 (en) 2002-04-11
EP1139751A1 (en) 2001-10-10

Similar Documents

Publication Publication Date Title
FR2727867B1 (fr) Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux
ZA958686B (en) Viral vectors and use in gene therapy
WO2000020557A3 (en) GEMINIVIRUS VECTORS FOR GENE EXPRESSION IN PLANTS
EP0981649A4 (en) PEPTIDES THAT IMPROVE THE TRANSPORT OF AN ACTIVE ACTIVE SUBSTANCE THROUGH TISSUES, AND COMPOSITIONS AND METHODS USING THE SAME
AU5557501A (en) Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
IL131209A0 (en) Recombinant haloaliphatic dehalogenases
IT1291135B1 (it) Vettori ricombinanti utilizzabili in terapia genica
DK0977877T3 (da) Forbedringer vedrörende genekspressionsspecificitet
FR2818481B1 (fr) Teletraitement et distribution d'images dans des kiosques
AP2001002189A0 (en) Genes and proteins and their uses
FR2755699B1 (fr) Nouvelles constructions et vecteurs pour l'expression ciblee et inductible des genes
HUP9901749A3 (en) Gene conferring disease resistance in plants and uses thereof
EP1186615A4 (en) PROTEIN AND DNA OF THIS PROTEIN
IL117466A0 (en) Recombinant viruses expressing lecithin-cholesterol acryltransferase and their use in gene therapy
IT9020072A0 (it) Cellule umane per l'elevata espressione di geni inseriti in dna ricombinanti episomiali,loro preparazione e loro impiego
EP1064947A4 (en) IN OVO VACCINATION AGAINST MAREK'S DISEASE VIRUS, TYPE 1
FR2759708B1 (fr) Moyens pour identifier, isoler et caracteriser des sequences nucleotidiques impliquees dans l'apomixie
NO971521L (no) Adenovirus-avledede, virale vektorer med to terapeutiske gener, et selvmordsgen og et immunopotensierende gen
HUP0201660A2 (en) Novel polypeptide and dna thereof
EP1162887A4 (en) GENE TRANSFER BY RECOMBINANT ADENO-ASSOCIATED VIRUS INFLUENCING DEMYELINIZATION
FR2766145B1 (fr) Attache de levage et groupe moto-propulseur equipe d'une telle attache
EP1181316A4 (en) DNA WHICH CODES FOR SNORF36A AND SNORF36B RECEPTORS
FR2795732B1 (fr) Utilisation du gene krit1 dans le domaine de l'angiogenese
EP1142999A4 (en) PROTEIN AND ITS DNA
EP1042000A4 (en) TRANSFER OF MULTIPLE GENES TO CELLS USING MULTIPLE ADENO-ASSOCIATED VIRAL VECTORS

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010726

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20030204

17Q First examination report despatched

Effective date: 20031103

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20090312